Cost-Effectiveness Analysis of Interventional Liver-Directed Therapies for a Single, Small Hepatocellular Carcinoma in Liver Transplant Candidates

被引:3
作者
Wu, Xiao [1 ]
Heller, Michael [1 ]
Kwong, Allison [3 ]
Fidelman, Nicholas [1 ]
Mehta, Neil [2 ]
机构
[1] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Gen Hepatol & Liver Transplantat, 513 Parnassus Ave,Room S-357, San Francisco, CA 94143 USA
[3] Stanford Univ, Dept Gastroenterol & Hepatol, San Francisco, CA USA
关键词
TRANSARTERIAL CHEMOEMBOLIZATION; RADIOFREQUENCY ABLATION; TRENDS; RESECTION; OUTCOMES; SCORE; Y-90;
D O I
10.1016/j.jvir.2023.02.016
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To assess the cost effectiveness of 3 main locoregional therapies (LRTs) (transarterial chemoembolization [TACE], transarterial radioembolization [TARE], and percutaneous ablation) as bridging therapy.Materials and Methods: A cost-effectiveness analysis was performed comparing the 3 LRTs for patients with a single hepatocellular carcinoma (HCC) with a diameter of 3 cm or less over a 5-year time horizon from a payer's perspective. The clinical courses, including transplantation, decompensation resulting in delisting, and the need for a second LRT, were based on data from the United Network for Organ Sharing (2016-2019). Costs and effectiveness were measured in U.S. dollars and quality-adjusted life-years, respectively. Probabilistic and deterministic sensitivity analyses were performed. Results: A total of 2,594, 1,576, and 903 patients underwent TACE, ablation, and TARE, respectively. Ablation was the dominant strategy, with the lowest expected cost and highest effectiveness. The probabilistic sensitivity analysis demon-strated that ablation was the most cost-effective strategy in 93.9% of simulations. A subgroup analysis was performed for different wait times, with ablation remaining the most cost-effective strategy. The sensitivity analysis showed that ablation was most effective if the risk of waitlist dropout was less than 2.00% and the rate of transplantation was more than 15.1% quarterly. TARE was most effective if the risk of dropout was less than 1.19% and the rate of transplantation was more than 24.0%. TACE was most effective if the risk of dropout was less than 1.01% and the rate of transplantation was more than 45.7%. Ablation remained the most cost-effective modality until its procedural cost was more than $34,843.Conclusions: Ablation is the most cost-effective bridging strategy for patients with a single, small (& LE;3 cm) HCC prior to liver transplantation. The conclusion remained robust in multiple sensitivity analyses.
引用
收藏
页码:1237 / 1246.e3
页数:13
相关论文
共 50 条
  • [21] Locoregional Therapies for Hepatocellular Carcinoma prior to Liver Transplant: Comparative Pathologic Necrosis, Radiologic Response, and Recurrence
    Mosenthal, Mckenzie
    Adams, William
    Cotler, Scott
    Ding, Xianzhong
    Borge, Marc
    Malamis, Angelo
    Lee, David
    Thomas, Tarita
    Jawahar, Anugayathri
    Amin, Parag
    Molvar, Christopher
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2024, 35 (04) : 506 - 514
  • [22] Integration of Systemic and Liver-Directed Therapies for Locally Advanced Hepatocellular Cancer: Harnessing Potential Synergy for New Therapeutic Horizons
    Bent, Eric H.
    Wehrenberg-Klee, Eric
    Koay, Eugene J.
    Goyal, Lipika
    Wo, Jennifer Y.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (05): : 567 - +
  • [24] Comparing Simultaneous Liver-Kidney Transplant Strategies: A Modified Cost-Effectiveness Analysis
    Cheng, Xingxing S.
    Kim, W. Ray
    Tan, Jane C.
    Chertow, Glenn M.
    Goldhaber-Fiebert, Jeremy
    TRANSPLANTATION, 2018, 102 (05) : E219 - E228
  • [25] Differential Impact of Age Among Liver Transplant Candidates With and Without Hepatocellular Carcinoma
    Cullaro, Giuseppe
    Rubin, Jessica B.
    Mehta, Neil
    Lai, Jennifer C.
    LIVER TRANSPLANTATION, 2020, 26 (03) : 349 - 358
  • [26] Comparison of Wait-List Mortality Between Cholangiocarcinoma and Hepatocellular Carcinoma Liver Transplant Candidates
    Ziogas, Ioannis A.
    Hickman, Laura A.
    Matsuoka, Lea K.
    Izzy, Manhal
    Montenovo, Martin I.
    Rega, Scott A.
    Feurer, Irene D.
    Alexopoulos, Sophoclis P.
    LIVER TRANSPLANTATION, 2020, 26 (09) : 1112 - 1120
  • [27] Cost-Effectiveness of a Serum Biomarker Test for Risk-Stratified Liver Ultrasound Screening for Hepatocellular Carcinoma
    Carter, Hannah E.
    Jeffrey, Gary P.
    Ramm, Grant A.
    Gordon, Louisa G.
    VALUE IN HEALTH, 2021, 24 (10) : 1454 - 1462
  • [28] Posttransplant Hepatocellular Carcinoma Surveillance A Cost-effectiveness and Cost-utility Analysis
    Hessheimer, Amelia J.
    Vargas-Martinez, Ana Magdalena
    Trapero-Bertran, Marta
    Navasa, Miquel
    Fondevila, Constantino
    ANNALS OF SURGERY, 2023, 277 (02) : E359 - E365
  • [29] The cost-effectiveness analysis of laparoscopic hepatectomy compared with open liver resection in the early stage of hepatocellular carcinoma: a decision-analysis model in Thailand
    Singhirunnusorn, Jumpol
    Niyomsri, Siwaporn
    Dilokthornsakul, Piyameth
    HPB, 2022, 24 (02) : 183 - 191
  • [30] Cost-effectiveness analysis of liver transplantation in biliary atresia according to the severity of end-stage liver disease
    Sihaklang, Boonyanurak
    Getsuwan, Songpon
    Pattanaprateep, Oraluck
    Butsriphum, Napapat
    Lertudomphonwanit, Chatmanee
    Tanpowpong, Pornthep
    Thirapattaraphan, Chollasak
    Treepongkaruna, Suporn
    BMC PEDIATRICS, 2023, 23 (01)